Table 5 Crude incidence and 95% CIs of serious infection (n = 21,832)
From: Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
Drug therapy | Events | Total person-years | Crude rate (per 100 patient-year) | 95% CI |
|---|---|---|---|---|
DMARDs | 104 | 5196.02 | 2.01 | 1.65–2.42 |
TNFi ± DMARDs | 490 | 22,736.79 | 2.16 | 1.98–2.36 |
Non-TNF biologic ± DMARDs | 173 | 6936.41 | 2.49 | 2.14–2.88 |
Tofacitinib ± DMARDs | 17 | 474.48 | 3.67 | 2.21–5.75 |